Aim of the Stockholm 3 test
The Stockholm 3 test aims to detect aggressive prostate cancer at the earliest possible stage. For most men, early detection is the key to being able to cure prostate cancer with a high probability. The classic PSA test is influenced by many factors and can also increase due to benign prostate diseases. As a result, there is a risk of unnecessary and stressful follow-up examinations for the patient.
How does the Stockholm-3 test work?
Like the PSA test, the Stockholm 3 test is a blood test. This means that men only have to provide a blood sample, which is then analysed in the laboratory. The Stockholm 3 test combines various protein markers, genetic markers and patient data in a scientifically tested algorithm. The result is a risk score that indicates the probability of the presence of aggressive prostate cancer.
For which men is the Stockholm 3 test suitable?
The test is suitable for men aged 45-74 years with a PSA value between 1.5 - 20 ng/ml who want to assess the risk of prostate cancer in case of suspicion.
Are the costs covered by health insurance?
The cost of the Stockholm 3 test is currently not covered by health insurance and amounts to around CHF 500. Interested men must therefore pay for it themselves.
The Swedish research team assumes that the test will ultimately help to save costs. In a study with more than 75,000 male participants, it was shown that the test reduced the number of unnecessary prostate biopsies by 50% and the number of MRI examinations by 60%.
You are welcome to make an appointment for further discussion.
Contact us
Claraspital Urology
Urology office
+41 61 685 85 23
urology(at)claraspital.ch